Cargando…

Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn’s disease: a Chinese real-world study

BACKGROUND: Ustekinumab (UST), a newly-used biologic targeting p40 subunit of IL12 and IL23 in China, exerts a confirmed therapeutic effect on the induction and maintenance therapies for refractory Crohn’s disease (CD). Therapeutic drug monitoring based on trough and antibody concentration is of cor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Jia-yin, Zhang, Min, Wang, Wei, Peng, Xiang, Zhao, Jun-zhang, Liu, Tao, Li, Zhi-wei, Sun, Hai-tian, Hu, Pinjin, Zhi, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522105/ https://www.ncbi.nlm.nih.gov/pubmed/34663208 http://dx.doi.org/10.1186/s12876-021-01946-8

Ejemplares similares

Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
por: Yao, Jiayin, et al.
Publicado: (2023)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
por: Yao, Jiayin, et al.
Publicado: (2023)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
por: Chien, Tzu Hsiang, et al.
Publicado: (2021)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
por: Scribano, Maria Lia, et al.
Publicado: (2022)

A150 ASSOCIATION BETWEEN SERUM USTEKINUMAB CONCENTRATIONS AND ENDOSCOPIC DISEASE ACTIVITY IN CROHN’S DISEASE
por: Yanofsky, R, et al.
Publicado: (2022)

Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease
por: Haider, Syedreza A., et al.
Publicado: (2020)

Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022)

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
por: Chaparro, María, et al.
Publicado: (2022)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
por: Cohen, Alexandra, et al.
Publicado: (2021)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients
por: Mechie, Nicolae-Catalin, et al.
Publicado: (2021)

Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis
por: Godoy Brewer, Gala M, et al.
Publicado: (2021)

Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease
por: Forss, Anders, et al.
Publicado: (2022)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease
por: Buisson, Anthony, et al.
Publicado: (2021)

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
por: Saman, Sadik, et al.
Publicado: (2019)

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
por: Rubín de Célix, Cristina, et al.
Publicado: (2022)

Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn’s Disease
por: Verdon, Christine, et al.
Publicado: (2020)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Correlation between Treatment Outcomes and Serum Vitamin D Levels As Well As Infliximab Trough Concentration among Chinese Patients with Crohn's Disease
por: Song, Xiaomei, et al.
Publicado: (2023)

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020)

Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort
por: Kubesch, Alica, et al.
Publicado: (2019)

Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023)

A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease
por: Bennett, Audrey, et al.
Publicado: (2020)

Prediction of Tacrolimus Dose/Weight-Adjusted Trough Concentration in Pediatric Refractory Nephrotic Syndrome: A Machine Learning Approach
por: Mo, Xiaolan, et al.
Publicado: (2022)

Ustekinumab in ulcerative colitis‐ insights from the real‐world data
por: Veisman, Ido, et al.
Publicado: (2022)

Polymorphisms of the TNF Gene and Three Susceptibility Loci Are Associated with Crohn’s Disease and Perianal Fistula Crohn’s Disease: A Study among the Han Population from South China
por: Zhang, Min, et al.
Publicado: (2019)

Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children
por: Zhao, Yi-Chang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_umln884nhhad12avvgcgqmkdcu